Is TRGNF or RYLD a better dividend investment in 2026?

TRGNF currently yields 200.00% with a 5% 5-year dividend growth rate. RYLD yields 4.00% with 5% growth. The better choice depends on your goal: TRGNF offers higher current income.

What is the dividend yield difference between TRGNF and RYLD?

TRGNF has a forward dividend yield of 200.00% ($2.00/share annually). RYLD yields 4.00% ($2.00/share annually). The yield gap is 196.00 percentage points.

Home › Compare › TRGNF vs RYLD

TRGNF vs RYLD: Dividend Comparison 2026

TRGNF yields 200.00% · RYLD yields 4.00%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 TRGNF wins by $119.34M in total portfolio value

INVESTMENT

TIME HORIZON10 years

TRGNF

● Live price

200.00%

Share price

$1.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$119.36M

Annual income

$60,176,096.29

Full TRGNF calculator →

RYLD

● Live price

4.00%

Share price

$50.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.0K

Annual income

$899.19

Full RYLD calculator →

Portfolio growth — TRGNF vs RYLD

📍 TRGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	TRGNF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, TRGNF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

TRGNF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRGNF

Annual income on $10K today (after 15% tax)

$17,000.00/yr

After 10yr DRIP, annual income (after tax)

$51,149,681.85/yr

RYLD

Annual income on $10K today (after 15% tax)

$340.00/yr

After 10yr DRIP, annual income (after tax)

$764.31/yr

At 15% tax rate, TRGNF beats the other by $51,148,917.54/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRGNF + RYLD for your $10,000?

TRGNF: 50%RYLD: 50%

100% RYLD50/50100% TRGNF

Portfolio after 10yr

$59.70M

Annual income

$30,088,497.74/yr

Blended yield

50.40%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRGNF buys

RYLD buys

No recent congressional trades found for TRGNF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTRGNFRYLD

Forward yield	200.00% ✓	4.00%
Annual dividend / share	$2.00	$2.00
Payout ratio	50%	50%
1-year div growth	0%	5% ✓
5-year div CAGR	0%	5% ✓
Portfolio after 10y	$119.36M ✓	$28.0K
Annual income after 10y	$60,176,096.29 ✓	$899.19
Total dividends collected	$112.49M ✓	$6.4K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: TRGNF vs RYLD ($10,000, DRIP)

Year	TRGNF Portfolio	TRGNF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$30,700	$20,000.00	$11,120	$420.00	+$19.6K → TRGNF
2	$90,232	$57,383.18	$12,357	$458.31	+$77.9K → TRGNF
3	$254,173	$157,624.56	$13,721	$499.76	+$240.5K → TRGNF
4	$686,927	$414,961.74	$15,227	$544.58	+$671.7K → TRGNF
5	$1,783,118	$1,048,106.39	$16,885	$593.02	+$1.77M → TRGNF
6	$4,450,613	$2,542,677.12	$18,713	$645.34	+$4.43M → TRGNF
7	$10,693,420	$5,931,263.38	$20,724	$701.81	+$10.67M → TRGNF
8	$24,760,608	$13,318,648.86	$22,938	$762.73	+$24.74M → TRGNF
9	$55,315,649	$28,821,798.66	$25,372	$828.41	+$55.29M → TRGNF
10	$119,363,841	$60,176,096.29	$28,047	$899.19	+$119.34M → TRGNF

TRGNF vs RYLD: Complete Analysis 2026

TRGNF — Stock

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Full TRGNF Calculator →

RYLD — ETF

RYLD is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in RYLD shares.

Full RYLD Calculator →

📬

Get this TRGNF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRGNF vs SCHD TRGNF vs JEPI TRGNF vs O TRGNF vs KO TRGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.